Is Halozyme Therapeutics, Inc. (NASDAQ:HALO) a buy in 2026?
Yes, on balance. The Compass leans toward accumulating Halozyme Therapeutics, Inc. at current levels.
The invisible toll-booth on Big Pharma's subcutaneous shift, trading like a patent cliff is here when the runway extends to 2032.
Where HALO is headed
Halozyme's enzyme, rHuPH20, has become the default answer to a question every Big Pharma oncology and immunology franchise is now forced to ask: how do we convert this $5B IV blockbuster into a subcutaneous version before biosimilars eat us alive? The answer is a royalty cheque to San Diego. DARZALEX SC now represents over 95% of total DARZALEX sales for Johnson & Johnson, Roche's Ocrevus SC and Tecentriq SC are ramping into 2027, and argenx's Vyvgart Hytrulo has become the SC standard in generalised myasthenia gravis. By late 2027, royalty revenue alone should clear $1.2B at >90% incremental margins, with operating margins pushing past 55%.
Read the full Compass Direction on HALO
The complete destination call, the overlooked angle, milestones, and bull, base, and bear price scenarios (around $71.48).
See the full HALO analysisGet calls like this, free
Join the Alexandria e-letter for forward-looking verdicts, earnings intelligence, and the contrarian reads the crowd misses. Twice a week, no noise.
Free forever. Unsubscribe anytime. We never share your email.
Frequently asked questions
Is Halozyme Therapeutics, Inc. (NASDAQ:HALO) a buy in 2026?
Yes, on balance. The Compass leans toward accumulating Halozyme Therapeutics, Inc. at current levels. The invisible toll-booth on Big Pharma's subcutaneous shift, trading like a patent cliff is here when the runway extends to 2032.
What is HALO's Compass Score?
Halozyme Therapeutics, Inc. scores 88/100 on Alexandria's Compass, placing it in the "True North" tier. Scores blend eight factors and update weekly.
What is the price target for HALO?
Alexandria's full Compass Direction includes bull, base, and bear price scenarios with the valuation math behind each. Read the full breakdown on the HALO page.
Compass verdicts are AI-generated, forward-looking editorial research from publicly available data, not investment advice or a recommendation regarding any security. Scores and verdicts update as the data changes.